Investigators reported Phase 2 peri-operative results for pembrolizumab combined with lenvatinib in mucosal melanoma, a setting with limited effective options. The study, led by Mao, Lai, Zheng and colleagues and published in Nature Communications, evaluated the combination as a treatment approach around surgery. The trial design targets a clinical gap in a rare but aggressive subtype, where standard treatment paradigms often fail to deliver durable control. Results were described as promising in the provided summary materials. The report supports continued exploration of checkpoint inhibitor plus multikinase inhibitor combinations in rare tumor biology, particularly where peri-operative strategies may influence outcomes through earlier immune engagement and disease burden reduction.